Hero image with Pittsburgh background pittplusme.org/study/1095

STUDY BASICS

Do you have advanced stage non-small cell lung cancer (NSCLC) and have not previously been treated with other drugs? If so, you may be eligible to participate in a study to see if an investigational drug is safe, if it prevents your lung cancer from growing, and how long it works. Involves a screening period to see if you are eligible and up to 12 months of treatment.


IRB:
  STUDY19050393 - 16-054: A phase II clinical trial evaluating the safety and efficacy of durvalumab (MEDI4736) as 1st line therapy in advanced non-small cell lung cancer (NSCLC) patients with Eastern Cooperative Oncology Group (ECOG) performance status of 2

Age Range
AGE:   18 and up

Compensation COMPENSATION: 

NONE

Phone Number PHONE NUMBER:
1-866-438-8230
SHARE STUDY
Printer Printer   Email A FriendEmail A Friend   ShareShare   TweetTweet   Linked-InLinked-In
Search Icon pittplusme.org/study/1095
OR
Phone Number PHONE NUMBER:
1-866-438-8230

PittPlusMe.org 1-866-438-8230 PittPlusMe@pitt.edu
@PittPlusMe share tweet